Clinical Trial Update: Three-Dose Regimen of MRKAd5+6 Trigene (V526) in Healthy Adults (V526-001)(COMPLETED) [Phase 1]

View source ↗

Summary

This update notes the completion of a Phase 1 trial evaluating a three-dose regimen of the MRKAd5+6 Trigene (V526) vaccine in healthy adults for HIV infection.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• MRKAd5+6 Trigene (V526)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: HIV, HIV Infections | Phase 1 | Status: COMPLETED